2026.03.20
Meet Us at AACR 2026.
Therapeutic restoration of p53 via engineered synthetic mRNA analogs in p53 mutant cancer
- Presentation Number
- 345
- Session
- Mechanism-Guided Development of Targeted Cancer Therapies, Apr. 19 at 14:00~17:00 PM
- Presenter
-
Yong Ho Heo, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Breaking the KRAS inhibitor induced resistance-wall: Targeting KRAS-SOS1 to disarm hypoxic survival
- Presentation Number
- 441
- Session
- Novel Therapeutics and Drug Targets 1, Apr. 19 at 14:00-17:00 PM
- Presenter
-
Jongmin Hong, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Non-clinical characteristics of BH3120, a clinical stage bispecific antibody targeting PD-L1 and 4-1BB, in combination with CD3 T cell engagers
- Presentation Number
- 1549
- Session
- Combination Immunotherapies, Apr. 20 at 9:00~12:00 PM
- Presenter
-
Jing Wang /
Beijing Hanmi Pharmaceutical Co., Ltd.
A transcriptomic framework to predict response and prioritize indications for p53 restoration therapy
- Presentation Number
- 2701
- Session
- Application of Bioinformatics to Cancer Biology 3, Apr. 20 at 14:00~17:00 PM
- Presenter
-
Hosun Lee /
Hanmi Pharmaceutical Co., Ltd.
Next-generation STING mRNA therapy with reduced toxicity and dual action against cancer by boosting immunity and inducing tumor cell death
- Presentation Number
- 4302
- Session
- Immunomodulatory Agents, Apr. 21 at 9:00 AM~12:00 PM
- Presenter
-
Youngjin Han, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Preclinical evaluation of BH4601, a novel tetravalent PD-L1 and B7H3 bispecific antibody-drug conjugate (ADC) with Topo1 inhibitor for the treatment of solid tumors
- Presentation Number
- 5756
- Session
- Multi-Axis Antineoplastic Agents, Apr. 21 at 14:00~17:00 PM
- Presenter
-
Jun Wang /
Beijing Hanmi Pharmaceutical Co., Ltd.
Machine learning and structure-guided discovery of EP300-selective, orally bioavailable degraders for cancer therapy
- Presentation Number
- 5782
- Session
- Proximity-Induced Drug Discovery 2, Apr. 21 at 14:00~17:00 PM
- Presenter
-
Ho Yeon Nam, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Structure- and bioinformatics-driven development of a selective, orally bioavailable HER2 small molecule inhibitor (HM100714) for cancer therapy
- Presentation Number
- 5882
- Session
- Tyrosine Kinase, Phosphatase, and Other Inhibitors, Apr. 21 at 14:00~17:00 PM
- Presenter
-
Jiyoung Jeon, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Synergistic effects of HM97662 as an EZH1/2 dual inhibitor combined with DNA-damaging agents on malignant lung cancers harboring SMARCA4-deficiency
- Presentation Number
- 7055
- Session
- Epigenetic Modulator 2, Apr. 22 at 9:00 AM~12:00 PM
- Presenter
-
Seung Hyun Jung, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
